We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
-17.86%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$2.26B
AUM Growth
-$464M
Cap. Flow
+$97.5M
Cap. Flow %
4.32%
Top 10 Hldgs %
30.92%
Holding
158
New
12
Increased
35
Reduced
23
Closed
24

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$50.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$28.2M
3
ZGNX
Zogenix, Inc.
ZGNX
+$21.7M
4
TLND
Talend S.A. American Depositary Shares
TLND
+$18.7M
5
TWLO icon
Twilio
TWLO
+$17.9M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$26.2M
2
ECYT
Endocyte, Inc. Common Stock
ECYT
+$23.3M
3
MIC
Macquarie Infrastructure Holdings, LLC
MIC
+$19.7M
4
SLDB icon
Solid Biosciences
SLDB
+$18.9M
5
SNA icon
Snap-on
SNA
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 42.75%
2 Technology 23.08%
3 Consumer Discretionary 10.05%
4 Industrials 6.38%
5 Communication Services 2.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STKL
51
DELISTED
SunOpta
STKL
$16.6M 0.74%
4,300,540
– –
GBT
52
DELISTED
Global Blood Therapeutics, Inc.
GBT
$15.1M 0.67%
367,000
+137,000
+60% +$5.13M
TECX
53
Tectonic Therapeutic
TECX
$538M
$14.9M 0.66%
77,408
– –
DNTH icon
54
Dianthus Therapeutics
DNTH
$6.16B
$14.8M 0.66%
165,676
+25,795
+18% +$3.52M
MYOK
55
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$14.8M 0.65%
302,000
– –
ANET icon
56
Arista Networks
ANET
$215B
$14.5M 0.64%
1,100,800
+44,800
+4% +$643K
TLND
57
DELISTED
Talend S.A. American Depositary Shares
TLND
$14.4M 0.64%
+388,033
New +$18.7M
VKTX icon
58
Viking Therapeutics
VKTX
$3.84B
$13.4M 0.6%
1,757,000
+967,000
+122% +$11.6M
HASI icon
59
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.85B
$13.3M 0.59%
698,000
-54,000
-7% -$1.16M
PFPT
60
DELISTED
Proofpoint, Inc.
PFPT
$13.2M 0.59%
158,000
– –
FOLD
61
DELISTED
Amicus Therapeutics
FOLD
$12.8M 0.57%
1,336,000
+636,000
+91% +$6.99M
CRUS icon
62
Cirrus Logic
CRUS
$6.65B
$12.3M 0.54%
370,000
– –
VCYT icon
63
Veracyte
VCYT
$4.77B
$11.7M 0.52%
930,000
-1,203,500
-56% -$14.2M
NBIX icon
64
Neurocrine Biosciences
NBIX
$18.7B
$11.1M 0.49%
156,000
– –
STRO icon
65
Sutro Biopharma
STRO
$411M
$10.9M 0.48%
124,490
– –
VMC icon
66
Vulcan Materials
VMC
$35.2B
$10.9M 0.48%
110,000
– –
RCKT icon
67
Rocket Pharmaceuticals
RCKT
$351M
$10.5M 0.46%
708,600
+314,015
+80% +$5.21M
STML
68
DELISTED
Stemline Therapeutics, Inc.
STML
$10.3M 0.46%
1,086,400
– –
IFRX icon
69
InflaRx
IFRX
$253M
$10M 0.44%
275,000
– –
ASAP
70
DELISTED
Waitr Holdings Inc. Common Stock
ASAP
$9.77M 0.43%
+43,800
New +$9.97M
KNSA icon
71
Kiniksa Pharmaceuticals
KNSA
$6.1B
$8.96M 0.4%
319,000
– –
BCRX icon
72
BioCryst Pharmaceuticals
BCRX
$2.35B
$8.45M 0.37%
1,047,000
– –
CTAS icon
73
Cintas
CTAS
$82.7B
$8.4M 0.37%
+200,000
New +$8.94M
EXAS
74
DELISTED
Exact Sciences
EXAS
$8.27M 0.37%
131,000
– –
ARYAU
75
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
$8.19M 0.36%
+800,000
New +$8.23M
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Eventide Asset Management held 158 positions worth $2.26B, down 17% from $2.72B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Eventide Asset Management deployed $97.5M of net new capital in Q4 2018, opening 12 new positions and adding to 35 existing holdings. Its largest new stake was Talend S.A. American Depositary Shares: 388,033 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Macquarie Infrastructure Holdings, LLC, an estimated $19.7M trimmed.

  • Eventide Asset Management's largest Q4 2018 buy was Talend S.A. American Depositary Shares: 388,033 shares worth $14.4M.
  • Eventide Asset Management added most to Sage Therapeutics in Q4 2018, an estimated $50.6M increase.
  • Eventide Asset Management's biggest Q4 2018 reduction was Macquarie Infrastructure Holdings, LLC, cutting an estimated $19.7M.
  • Eventide Asset Management fully exited AnaptysBio in Q4 2018, selling an estimated $26.2M.
  • Eventide Asset Management's ten largest holdings make up 31% of its $2.26B portfolio in Q4 2018.
  • Eventide Asset Management opened 12 new positions and closed 24 in Q4 2018.
  • Eventide Asset Management's portfolio value fell 17% quarter-over-quarter to $2.26B.

Based on Eventide Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.